News
1h
Barchart on MSNAre Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...
AbbVie stands to benefit from a policy change eliminating the “pill penalty” in Medicare’s drug price negotiations, offering ...
AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...
AbbVie (NYSE:ABBV) recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.
Two A+ stocks investors should consider are Alphabet (GOOG) and AbbVie (ABBV). Alphabet is the top mega-cap stock. It posted ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key ...
While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.
Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. AbbVie beat Wall Street's top- and bottom-line estimates. President Trump told attendees at the National Republican ...
AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...
AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...
We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results